Skip to main content

Illumina cash and equivalents

  • ILMN · Nasdaq
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$198.26−4.22%Close 16 Nov 2026 · Market value $30.43B

Illumina's cash and equivalents was $1.42 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), up 25.8% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 27 Sep 2026) it was $1.29 billion, up 22.8% from a year earlier.

From Illumina's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Fiscal 2025
$1.42B
+25.8%
Q3 FY2026
$1.29B
+22.8% on a year
Growth over 9 years
+7.6%
a year, FY 2016–FY 2025

Cash and equivalents by fiscal year

$735MFY 2016$1.23BFY 2017+66.7%$1.14BFY 2018−6.6%$2.04BFY 2019+78.5%$1.81BFY 2020−11.4%$1.23BFY 2021−31.9%$2.01BFY 2022+63.2%$1.05BFY 2023−47.9%$1.13BFY 2024+7.5%$1.42BFY 2025+25.8%

Change on the year before, under each year. From FY 2016 to FY 2025, Illumina's cash and equivalents went from $735 million to $1.42 billion, a compound annual change of +7.6%; the highest was $2.04 billion in FY 2019.

Illumina cash and equivalents, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$735M$1.23B$1.14B$2.04B$1.81B$1.23B$2.01B$1.05B$1.13B$1.42B
Period end1 Jan 201731 Dec 201730 Dec 201829 Dec 20193 Jan 20212 Jan 20221 Jan 202331 Dec 202329 Dec 202428 Dec 2025

Cash and equivalents by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Illumina cash and equivalents, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$1.13B$1.11B$934M$1.05B$1.42B$1.09B$1.04B$1.29B
Period end29 Dec 202430 Mar 202529 Jun 202528 Sep 202528 Dec 202529 Mar 202628 Jun 202627 Sep 2026

How cash and equivalents is measured

Cash and equivalents is the cash the company holds at the end of the period and the investments it can turn into cash within three months. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Illumina's other figures

Cash and equivalents of comparable companies

Everything on ILMN, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.